Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Prereactivation propranolol reduces PTSD symptoms

14 May 2018
Mind training is the key to prevent PTSD among emergency responders handling trauma cases

Prereactivation propranolol, a treatment protocol suggested by reconsolidation theory, shows potential in reducing symptoms of post-traumatic stress disorder (PTSD), a recent study has shown.

There was a statistically significant 11.50 estimated group difference in post-treatment Clinician-Administered PTSD Scale (CAPS) score, adjusted for pretreatment values (analysis of covariance). The within-group pre- to post-treatment effect sizes (Cohen’s d) were 1.76 and 1.25 for propranolol and placebo, respectively.

The mixed linear model’s estimated time-by-group interaction for the patient-rated PTSD Checklist–Specific (PCL-S) generated an average decrease of 2.43 points per week. The total significant difference was 14.58 points above that of placebo. The pre- to post-treatment effect sizes were 2.74 and 0.55 for propranolol and placebo, respectively.

Analyses per protocol revealed similar significant results for both outcomes.

A total of 60 adults diagnosed with long-standing PTSD were included in this 6-week, double-blind, placebo-controlled, randomized clinical trial. The investigators administered propranolol or placebo 90 minutes before a brief memory reactivation session, once a week for 6 consecutive weeks.

They hypothesized a significant treatment effect of trauma reactivation with propranolol vs trauma reactivation with placebo in reducing PTSD symptoms on both the CAPS and PCL-S in an intention-to-treat analysis.

“Replication studies using a long-term follow-up in various trauma populations are required,” the investigators said.

A noradrenergic beta-receptor, propranolol has been used in this study as a putative reconsolidation blocker to reduce PTSD symptoms, they noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.